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Comparison of Effect of Lavandula 
officinalis and Venlafaxine in Treating 
Depression: A Double Blind Clinical Trial
IntROduCtIOn
Health Organization has projected that approximately 350 million 
people of all ages are suffering from depression. Most of these 
people are women [1]. Major Depressive Disorder (MDD) is a chronic 
disease which may be associated with other mental diseases and 
has a complicated pattern of resistance and recurrence [2,3]. For this 
reason, this disease disturbs the function and efficiency of affected 
people and therefore represents a major economic burden on health 
care systems [4]. Also, chronic diseases adversely affect the quality 
of life of the patient [5-9]. In addition to many complications and 
problems, suicide is one of the most dangerous outcomes of this 
disease [10].
Worldwide, depression is a prevalent mental disease and a 
major cause of disability. The treatment for depression is based 
mainly on the use of antidepressants and pharmacotherapy [11]. 
Most psychiatrists begin the treatment with a Serotonin-Specific 
Reuptake Inhibitor (SSRI). Pharmacotherapies include bupropion (a 
noradrenergic, dopaminergic drug with properties similar to those of 
stimulants), the SSRIs, norepinephrine (venlafaxine and duloxetine), 
nefazodone (a drug with serotoninergic properties), and tricyclics 
[12]. 
Among these drugs, venlafaxine is a relatively new drug which is 
different from other antidepressants. Venlafaxine is likely to have 
no or fewer complications, especially cholinergic, than other 
antidepressants or be more effective than the SSRIs in treating 
depression [13,14]. Headache, sleeplessness, nausea, dry mouth, 
dyspepsia, diarrhea, weakness, dizziness, constipation and 
decreased libido are the cardiogenic complications and convulsion 
is one of the side effects of venlafaxine [12,15,16]. 
Despite the progress achieved in pharmacotherapy, the symptoms 
remain to recover in a large proportion of people with depression, 
who undergo treatment with these drugs [17]. It is argued that 
antidepressants exert inhibitory effects and fail to treat the disease 
[18]. Therefore, it is necessary to find a useful therapeutic approach 
for the patients. 
Using medicinal plants to treat mental disorders and chronic 
diseases has recently become widespread [19-21]. Lavandula 
officinalis is a medicinal plant that is used to treat depression. L. 
officinalis is a plant of family Lamiaceae [22] and has long been 
used as antibacterial, antifungal and antidepressant. L. officinalis 
oil is sedative and is used to treat wound burns and stings [22]. 
L. officinalis flower has therapeutic uses. L. officinalis contains 
flavonoid components that affect benzodiazepine receptors [23]. 
The existence of certain components, such as linalool and linalyl 
acetate and the flavonoid, such as luteolin in Lavandula Vera, raises 
the possibility that L. officinalis may be effective on central nervous 
system. The linalool in L. officinalis causes increase in noradrenalin 
and dopamine and therefore helps to exert antidepressant effect 
[24]. Inhaling the odour of linalool, a significant component of L. 
officinalis, has sedative effects on both humans and animals [25].
The essential oil of L. officinalis contains monoterpenes (1-3%). 
The most important components are linalyl acetate (30%-55%), 
linalool (20%-35%), beta-ocimene, cineol, camphor, sesquiterpene, 
caryophyllene oxide, tannin, rosmarinic acid derivatives, coumarine 
and flavonoids [26]. 
Antidepressants may not be welcomed because of inducing several 
side effects in some people [27]; moreover, there are debates over 
the immunity and the side effects of the medicinal plants that are 
used to treat mental diseases [28]. Venlafaxine is a drug of choice 
to treat depression. To date, little research has been conducted 
on venlafaxine and no study has been conducted to compare the 
effects of venlafaxine with L. officinalis in depression. Therefore, it 
MaSoud NikfarjaM1, reza rakhShaN2, hourivaSh Ghaderi3
 
Keywords: Antidepressant, Depressive disorder, Medicinal plant
ABStRACt
Introduction: Major depressive disorder is a chronic disease 
which may be associated with other mental illnesses. 
Lavandula officinalis and venlafaxine, herbal and chemical 
drugs respectively, are used to treat depression. Despite 
pharmacotherapy, major depressive disorder has a complicated 
pattern of resistance and recurrence.
Aim: The aim of this study was to determine the effect of L. 
officinalis and venlafaxine in treating depression. 
Materials and Methods: For this study, 120 patients referred 
to the psychiatry clinic of the Shahrekord University of 
Medical Sciences, Shahrekord, Iran, were randomly selected. 
The participants were randomly assigned to three groups: 
venlafaxine (Control Group), venlafaxine + L. officinalis (L. 
officinalis Group), and venlafaxine + placebo (Placebo Group). 
All the patients underwent treatment for six weeks. Depression 
test was administered to the three groups at different time 
intervals before the treatment, four weeks after the treatment 
and at completion of the treatment. The data were analysed by 
SPSS version17.0.
Results: Depression scores of all the groups decreased over 
time (p=0.001). The depression scores were significantly 
different between the control and L. officinalis groups (p=0.004), 
and the control and placebo groups (p=0.002), but were not 
significantly different between the L. officinalis and placebo 
groups (p=0.95).
Conclusion: Adding L. officinalis or a placebo is equally effective 
in decreasing mean depression score and venlafaxine obviously 
decreased this score.
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indicated that the three groups were matched on age, gender, 
education level, and the place of residence (p>0.05) [Table/Fig-1].
The depression scores of the groups were measured at the three 
points of time. The repeated measures ANOVA indicated that the 
depression indices of the groups decreased over time (p<0.001). 
is necessary to find a useful therapeutic approach for the patients. 
This clinical trial was conducted to compare the therapeutic effects 
of venlafaxine and L. officinalis in people suffering from MDD.
MAtERIALS And MEthOdS
The study was a double-blind clinical trial and was conducted 
in 2015. The Ethics Committee of the Shahrekord University of 
Medical Sciences approved the protocol of the study (approval no. 
25-94 and IRCT201604116480N13). Study population consisted of 
the patients with mild to moderate MDD who were referred to the 
psychiatry clinic. The diagnosis was made by a structured clinical 
interview conducted by a psychiatrist according to the DSM-5 
criteria [29, 30]. The patients with a score of at least 17 on Hamilton 
Depression Rating Scale were diagnosed with depression and 
included in the study.
Withdrawal from the study or being under routine treatments for 
depression, allergy to L. officinalis, history of using antidepressants, 
L. officinalis, or any medicinal plants with antidepressant effects, 
psychosis, underlying diseases and substance abuse were 
considered for exclusion. From the people with inclusion criteria who 
provided written consent to participate in the study, 120 people were 
selected. Sampling was done gradually and purposively. After the 
research purpose was explained to the people, they were assigned 
to three groups by simple randomization. For single blinding purpose 
we administered placebo to one of the study groups.
The patients were divided into three groups: Venlafaxine (Control 
Group), venlafaxine + L. officinalis (L. officinalis Group), and venlafaxine 
+ placebo (Placebo Group). Control Group was administered with 
a routine treatment for depression, 37.5 mg venlafaxine, placebo 
group with 37.5 mg venlafaxine and peppermint (in a 1.5 gm tea bag 
placed in a cup of boiling water for 10-15 minutes and then taken 
with candy every 12 hours) (according to German pharmacopoeia), 
and case group with 37.5 g venlafaxine and L. officinalis (in a 1.5 
g tea bag placed in a cup of boiling water for 10-15 minutes and 
then taken with candy every 12 hours) (according to German 
pharmacopoiea).
The enrollment of the people and administration of the treatments 
were conducted within six months. The questionnaire of depression 
was administered to all the patients prior to the treatments and then 
at three and six weeks after initiation of the treatments depending 
on the day of referral.
The participants were followed up by the psychiatrist during the 
study. The psychiatrist examined them for side effects, depression 
symptoms, and the risk of suicide and recorded the relevant data. 
If the risk of suicide was diagnosed at any stage of treatment, they 
were immediately referred to the psychiatrist for treatment. The data 
were gathered through interview, the questionnaires of demographic 
characteristics, side effects and the Hamilton Depression Rating 
Scale. For ethical considerations, a form enlisting the side effects 
was provided to all the participants to record potential side effects. 
Concurrent validity yielded moderate to high correlation coefficients, 
0.55-0.96 and r=72 mdn, with clinical rating of psychiatric patients. 
The corresponding correlation coefficient was obtained 0.73 with 
the Hamilton Depression Rating Scale [31].
The scores 17-24 were considered mild depression, 25-30 moderate 
depression, and the total scores above 31 severe depression [32,33]. 
The data were analysed by descriptive statistics, chi-square, and 
t-test was used. Data analysis was conducted by SPSS version 
17.0.
RESuLtS
The data on the age, gender, education level, and place of residence 
were compared among the groups. The mean (standard deviation) 
age of the patients was 36.7±2.09, 38.2±2.32 and 34.9±2.16 in 
control, case and placebo respectively. There was no significant 
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[table/Fig-1]: Mean (Standard deviation) of demographic characteristics in the 
control, L. officinalis and placebo groups.
*chi square test used
The depression scores were significantly different between the control 
and L. officinalis groups (p=0.004), and the control and placebo 
groups (p=0.002), but were not significantly different between the 
L. officinalis and placebo groups (p=0.95). The depression scores 
of the groups were significantly different at different points of time 
[Table/Fig-2].
dISCuSSIOn
This study was conducted to determine the effects of venlafaxine 
and L. officinalis in treating people with depression at three points 
of time. 
In this study, the depression indices in Venlafaxine Group obviously 
decreased (from 1.04±0.01 at the baseline to 0.71±0.01 in the six 
weeks after treatment) while in L. officinalis and placebo groups, 
no significant difference in decreased depression scores at different 
intervals was seen (p>0.05). 
Also, a double-blind clinical trial to investigate the effects of L. 
officinalis tincture and imipramine in treating mild to moderate 
depression, found that the effect of the L. officinalis effect was 
lesser than the imipramine effect. However, combined imipramine 
and L. officinalis tincture was more effective than the imipramine 
alone [32]. Relevantly, another study using the Hamilton Depression 
Rating Scale to measure the depression severity, demonstrated that 
the mean depression indices of the case group, administered with 
citalopram and L. officinalis,  declined more notably than the control 
group, administered with citalopram alone, after eight weeks [33]. A 
study reported that L. officinalis cream could relieve anxiety, stress, 
and depression of pregnant women [34]. 
Animal studies have confirmed the antidepressant effects of L. 
officinalis. Kageyama A et al., found that the L. officinalis extract, 
administered at three points of time, caused decrease in the mice's 
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physical inactivity. This finding was comparable to the imipramine 
effect. Linalool, an effective aromatic component of L. officinalis, 
was removed during preparation. Rosmarinic acid and apigenin 
glycosides of L. officinalis, which were studied in Kageyama A et al., 
study, have similar effects to antidepressants [35].
Seol GH et al., study on the laboratory rats reported consistent 
findings [36] with the present study. Studies indicated that methanolic 
and aqueous extract of L. officinalis, exert sedative and hypnotic 
effects on Central Nervous System (CNS) and therefore can prevent 
psychological problems [37,38]. This effect could induce through 
decreasing amount of cortisol and increasing amount of serotonin 
[39]; However, high concentration (0.1 mg/ml) of L. officinalis, oil 
induced a neurotoxicity effect [40]. Many of the plant based products 
have several components at different therapeutic concentrations, 
which affect controlling their quality and dose of administration [41]. 
Depressions may be influenced by many factors and the duration of 
follow up of case group is likely to confound the findings.
The findings demonstrated that the depression indices of the three 
studied groups, control, L. officinalis and placebo declined over time. 
However, certain drugs and multiple drug therapy can have better 
effects on the treatment course in some patients [42]. Cipriani A et 
al., study found that citalopram had better effects than venlafaxine 
and the herbal drugs, such as hypericum, in treating MDD [43]. 
Depression may be associated with other mental illnesses and no 
consideration of such classification was a limitation of the present 
study. Because depression is a chronic disease and the effect 
duration of different drugs may vary, future studies are recommended 
to adopt a longer duration for administration of the drugs under 
study. Moreover, to obtain higher quality findings, future studies 
should examine the efficacy of a single drug or multiple drugs in a 
pilot study and then assign the patients into treatments of interest 
in main study. Toxicity is an important issue about the medicinal 
plants.
LIMItAtIOn
Other mental illnesses concomitant with depression was one of the 
limitations of this study.
COnCLuSIOn
Adding L. officinalis or a placebo is equally effective in decreasing 
mean depression score. In contrast, in Venlafaxine Group the 
decrease in mean depression score was more marked compared 
to the other groups.
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